LGC Announces New, Integrated, Global Portfolio Brand, Biosearch Technologies
Want to listen to this article for FREE?
Complete the form below to unlock access to ALL audio articles.
Read time: 1 minute
LGC’s Genomics division announced it is transforming its branding under LGC, Biosearch Technologies, a unified portfolio brand integrating optimised genomic analysis technologies and tools to accelerate scientific outcomes.
Biosearch Technologies will focus on further developing its capabilities in NGS and Nucleic Acid Chemistry, which build on expertise in existing genomic analysis applications such as genotyping, PCR and qPCR it promotes to Agrigenomics and Human Healthcare customers.
Brian Kim, President and Managing Director, Biosearch Technologies, said: “We believe the time is ripe to introduce a new unifying name that conveys our differentiated position in the market place.”
“We’ve seen considerable expansion and are reaching customers in more places around the world than ever before. As LGC, Biosearch Technologies continues to grow, it is important that we tell our collective story in a united and cohesive way.”
Biosearch Technologies will streamline products from across legacy brands to ensure that the tools work together for customer needs. The name “Biosearch Technologies” reflects the innovation and progressiveness of the brand and embodies a forward-looking and continuously developing offer from LGC.
In recent years, LGC’s Genomics division has seen rapid expansion through a series of targeted and strategic acquisitions. This approach has introduced a number of new products that support mission critical customer applications. Biosearch Technologies integrates these genomic analysis tools combining expertise in manufacturing and design of enzymes and oligonucleotides, instrumentation engineering, extraction chemistries, and reagent and consumable development under one brand to deliver innovation to the life science market.
Mark Dearden, Vice President of Strategy and Marketing, Biosearch Technologies, said: “Every day through capabilities in enzyme engineering, genotyping technologies or custom oligos, we support mission critical customer applications. We state mission critical because if we don’t deliver to our customers, it might mean that they cannot manufacture a kit for an infectious disease diagnostic or that they cannot deliver the data sets that reduce the time to complete plant breeding decisions. We are bringing our collective knowledge and expertise to propel us and our customers forward.”
Biosearch Technologies will focus on further developing its capabilities in NGS and Nucleic Acid Chemistry, which build on expertise in existing genomic analysis applications such as genotyping, PCR and qPCR it promotes to Agrigenomics and Human Healthcare customers.
Brian Kim, President and Managing Director, Biosearch Technologies, said: “We believe the time is ripe to introduce a new unifying name that conveys our differentiated position in the market place.”
“We’ve seen considerable expansion and are reaching customers in more places around the world than ever before. As LGC, Biosearch Technologies continues to grow, it is important that we tell our collective story in a united and cohesive way.”
Biosearch Technologies will streamline products from across legacy brands to ensure that the tools work together for customer needs. The name “Biosearch Technologies” reflects the innovation and progressiveness of the brand and embodies a forward-looking and continuously developing offer from LGC.
In recent years, LGC’s Genomics division has seen rapid expansion through a series of targeted and strategic acquisitions. This approach has introduced a number of new products that support mission critical customer applications. Biosearch Technologies integrates these genomic analysis tools combining expertise in manufacturing and design of enzymes and oligonucleotides, instrumentation engineering, extraction chemistries, and reagent and consumable development under one brand to deliver innovation to the life science market.
Mark Dearden, Vice President of Strategy and Marketing, Biosearch Technologies, said: “Every day through capabilities in enzyme engineering, genotyping technologies or custom oligos, we support mission critical customer applications. We state mission critical because if we don’t deliver to our customers, it might mean that they cannot manufacture a kit for an infectious disease diagnostic or that they cannot deliver the data sets that reduce the time to complete plant breeding decisions. We are bringing our collective knowledge and expertise to propel us and our customers forward.”
